Literature DB >> 21463793

A prospective phase II evaluation of esophageal stenting for neoadjuvant therapy for esophageal cancer: optimal performance and surgical safety.

Russell E Brown1, Abbas E Abbas, Susan Ellis, Shannon Williams, Charles R Scoggins, Kelly M McMasters, Robert C G Martin.   

Abstract

BACKGROUND: Many surgeons are reluctant to use esophageal stents during neoadjuvant therapy for esophageal cancer because of concerns about nutritional status, stent-related complications, or added difficulties during esophagogastrectomy. We hypothesized that esophageal stenting during neoadjuvant therapy allows for optimal nutritional intake without adversely affecting perioperative outcomes. STUDY
DESIGN: This study is a prospective, dual-institution, single-arm, phase II evaluation of esophageal cancer patients undergoing neoadjuvant therapy before resection. All patients had a self-expanding polymer stent placed before neoadjuvant therapy. We monitored dysphagia symptoms, nutritional status, stent-related complications, and perioperative complications during the course of therapy and 90 days postoperatively.
RESULTS: We enrolled 32 patients with dysphagia and weight loss who were eligible for neoadjuvant therapy. After stent placement, 2 patients had stent migrations requiring replacement. No erosive complications were observed. During the course of neoadjuvant therapy, we noted improvement in dysphagia, mild weight loss, and maintenance of performance status. At a median of 50 days (range 18 to 92 days) after completion of neoadjuvant therapy, 20 patients underwent margin-negative esophagogastrectomy (16 Ivor Lewis, 4 minimally invasive) without problems with stent removal or difficulty in surgical dissection. Twelve patients did not undergo resection due to development of metastases (n = 8) or rapid decline in functional status (n = 4). Major perioperative complications included pulmonary embolism (n = 2), chyle leak (n = 1), and bronchial injury (n = 1). No surgical complications were attributed to stent placement.
CONCLUSIONS: Use of esophageal stents during neoadjuvant therapy is safe and results in resolution of dysphagia, mild weight loss, and maintenance of performance status without an effect on intraoperative dissection, perioperative complications, or delay in resection after neoadjuvant therapy.
Copyright © 2011 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21463793     DOI: 10.1016/j.jamcollsurg.2010.12.026

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  9 in total

1.  Evaluation of quality of life following placement of self-expanding plastic stents as a bridge to surgery in patients receiving neoadjuvant therapy for esophageal cancer.

Authors:  Robert C G Martin; Robert M Cannon; Russell E Brown; Susan F Ellis; Sharon Williams; C R Scoggins; Abbas E Abbas
Journal:  Oncologist       Date:  2014-02-24

2.  Percutaneous radiological gastrostomy in esophageal cancer patients: a feasible and safe access for nutritional support during multimodal therapy.

Authors:  Williams Tessier; Guillaume Piessen; Nicolas Briez; Arianna Boschetto; Géraldine Sergent; Christophe Mariette
Journal:  Surg Endosc       Date:  2012-09-07       Impact factor: 4.584

Review 3.  Nutrition therapy issues in esophageal cancer.

Authors:  Keith R Miller; Matthew C Bozeman
Journal:  Curr Gastroenterol Rep       Date:  2012-08

4.  Preoperative malnutrition and prognosis after neoadjuvant chemotherapy followed by subsequent esophagectomy.

Authors:  Naoya Yoshida; Yoshifumi Baba; Hideo Baba
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

5.  The use of biodegradable (SX-ELLA) oesophageal stents to treat dysphagia due to benign and malignant oesophageal disease.

Authors:  Ewen A Griffiths; Catherine J Gregory; Kishore G Pursnani; Jeremy B Ward; Robert C Stockwell
Journal:  Surg Endosc       Date:  2012-03-07       Impact factor: 4.584

Review 6.  Robotic esophagectomy.

Authors:  Brett Broussard; John Evans; Benjamin Wei; Robert Cerfolio
Journal:  J Vis Surg       Date:  2016-08-10

7.  Preoperative Nutritional Assessment by Controlling Nutritional Status (CONUT) is Useful to estimate Postoperative Morbidity After Esophagectomy for Esophageal Cancer.

Authors:  Naoya Yoshida; Yoshifumi Baba; Hironobu Shigaki; Kazuto Harada; Masaaki Iwatsuki; Junji Kurashige; Yasuo Sakamoto; Yuji Miyamoto; Takatsugu Ishimoto; Keisuke Kosumi; Ryuma Tokunaga; Yu Imamura; Satoshi Ida; Yukiharu Hiyoshi; Masayuki Watanabe; Hideo Baba
Journal:  World J Surg       Date:  2016-08       Impact factor: 3.352

8.  Esophageal stenting in the setting of malignancy.

Authors:  Juan Carlos Martinez; Matthew M Puc; Roderick M Quiros
Journal:  ISRN Gastroenterol       Date:  2011-08-08

Review 9.  Palliative Endoscopic Therapy of Esophageal Cancer.

Authors:  Thomas Rabenstein
Journal:  Viszeralmedizin       Date:  2015-10-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.